ArticleScientific reports2025
Bioinformatics analysis to explore the potential prognostic utility of hsa-miR-103a-3p in head and neck squamous cell carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- LUCAT1 promotes stemness in head and neck squamous cell carcinoma by sponging miR-128.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck squamous cell carcinoma (HNSCC), the seventh most common cancer globally, has not yet seen an exploration of the specific role of hsa-miR-103a-3p. This study employs integrated bioinformatics analysis to investigate the function, regulatory patterns, and prognostic significance of hsa-miR-103a-3p in HNSCC. The Kaplan-Meier database was used for pan-cancer prognostic analysis of hsa-miR-103a-3p. Expression significance was assessed using the dbDEMC and GSE124566 dataset from GEO. TargetScan, RNA22, miRDB, and miRWalk identified potential targets, while GEPIA 2.0 provided differentially expressed genes (DEGs). Functional and pathway enrichment analyses were conducted using ShinyGO and KOBAS. Elevated hsa-miR-103a-3p expression correlated with poor overall survival and was upregulated in HNSCC tissues. Integration of four target prediction tools yielded 297 candidate genes. Among them, HOXD10, HMGA2, and THY1 showed the highest expression, whereas UBL3, AMOT, and PDK4 displayed low levels. UBE2Q1, ZFPM2, and ATXN1 demonstrated the strongest accessibility to hsa-miR-103a-3p binding. Network analysis revealed interactions with transcription factors and tumor-related genes, while enrichment highlighted involvement in upstream regulators and downstream cancer-associated pathways. This study identified 297 target genes and clarified the regulatory role of hsa-miR-103a-3p through interaction networks, transcription factor associations, and pathway enrichment. These findings suggest a potential oncogenic role for hsa-miR-103a-3p in modulating the cAMP signaling pathway, proteoglycans in cancer, and related mechanisms, thereby linking its molecular regulation to poor prognosis and potential therapeutic targeting in HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.